- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 480702, 14 pages
Elevated Expression of Fractalkine (CX3CL1) and Fractalkine Receptor (CX3CR1) in the Dorsal Root Ganglia and Spinal Cord in Experimental Autoimmune Encephalomyelitis: Implications in Multiple Sclerosis-Induced Neuropathic Pain
1Faculty of Pharmacy, University of Manitoba, Apotex Center 750, McDermot Avenue, Winnipeg, MB, Canada R3E 0T5
2Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada R3E 3P5
Received 30 April 2013; Revised 2 July 2013; Accepted 15 July 2013
Academic Editor: Carl Muroi
Copyright © 2013 Wenjun Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. P. Namaka, K. Ethans, B. Jensen, F. Esfahani, and E. E. Frost, “Multiple sclerosis,” in Therapeutic Choices/e-Therapeutic, pp. 309–319, Canadian Pharmacists Association, Ottawa, Canada, 2011.
- C. M. R. Acosta, C. Cortes, H. Macphee, and M. P. Namaka, “Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair,” CNS & Neurological Disorders. In press.
- W. Zhu, J. A. Le Dorze, M. Prout, E. E. Frost, and M. P. Namaka, “An overview of Relapsing Remitting Multiple Sclerosis (RRMS) and current treatment options,” Pharmacy Practice, vol. 9, 2010.
- M. J. Tullman, “Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis,” American Journal of Managed Care, vol. 19, supplement 2, pp. s15–s20, 2013.
- F. Begum, W. Zhu, C. Cortes, B. Macneil, and M. Namaka, “Elevation of tumor necrosis factor alpha in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis,” Journal of NeuroImmune Pharmacology, vol. 8, no. 3, pp. 677–690, 2013.
- R. M. Ransohoff, “Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology,” Immunity, vol. 31, no. 5, pp. 711–721, 2009.
- W. J. Karpus, “Chemokines and central nervous system disorders,” Journal of NeuroVirology, vol. 7, no. 6, pp. 493–500, 2001.
- C. Abbadie, S. Bhangoo, Y. De Koninck, M. Malcangio, S. Melik-Parsadaniantz, and F. A. White, “Chemokines and pain mechanisms,” Brain Research Reviews, vol. 60, no. 1, pp. 125–134, 2009.
- Y. Pan, C. Lloyd, H. Zhou et al., “Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation,” Nature, vol. 387, no. 6633, pp. 611–617, 1997.
- J. F. Bazan, K. B. Bacon, G. Hardiman et al., “A new class of membrane-bound chemokine with a CX3C motif,” Nature, vol. 385, no. 6617, pp. 640–642, 1997.
- G. A. Chapman, K. Moores, D. Harrison, C. A. Campbell, B. R. Stewart, and P. J. Strijbos, “Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage,” The Journal of Neuroscience, vol. 20, no. 15, p. RC87, 2000.
- J. K. Harrison, Y. Jiang, S. Chen et al., “Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 18, pp. 10896–10901, 1998.
- J. A. Lindia, E. McGowan, N. Jochnowitz, and C. Abbadie, “Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain,” Journal of Pain, vol. 6, no. 7, pp. 434–438, 2005.
- C. A. Haskell, W. W. Hancock, D. J. Salant et al., “Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection,” Journal of Clinical Investigation, vol. 108, no. 5, pp. 679–688, 2001.
- G. O. Ceyhan, S. Deucker, I. E. Demir et al., “Neural fractalkine expression is closely linked to pain and pancreatic neuritis in human chronic pancreatitis,” Laboratory Investigation, vol. 89, no. 3, pp. 347–361, 2009.
- Z. Zhuang, Y. Kawasaki, P. Tan, Y. Wen, J. Huang, and R. Ji, “Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine,” Brain, Behavior, and Immunity, vol. 21, no. 5, pp. 642–651, 2007.
- M. Yasuda, T. Ito, T. Oono et al., “Fractalkine and TGF-β1 levels reflect the severity of chronic pancreatitis in humans,” World Journal of Gastroenterology, vol. 14, no. 42, pp. 6488–6495, 2008.
- B. Lamb, “The roles of fractalkine signaling in neurodegenerative disease,” Molecular Neurodegeneration, vol. 7, supplement 1, p. L21, 2012.
- A. Nishiyori, M. Minami, Y. Ohtani et al., “Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?” FEBS Letters, vol. 429, no. 2, pp. 167–172, 1998.
- E. D. Milligan, E. M. Sloane, and L. R. Watkins, “Glia in pathological pain: a role for fractalkine,” Journal of Neuroimmunology, vol. 198, no. 1-2, pp. 113–120, 2008.
- G. M. Verge, E. D. Milligan, S. F. Maier, L. R. Watkins, G. S. Naeve, and A. C. Foster, “Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions,” European Journal of Neuroscience, vol. 20, no. 5, pp. 1150–1160, 2004.
- F. E. Holmes, N. Arnott, P. Vanderplank et al., “Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour,” Journal of Neurochemistry, vol. 106, no. 2, pp. 640–649, 2008.
- P. Hu, A. L. Bembrick, K. A. Keay, and E. M. McLachlan, “Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve,” Brain, Behavior, and Immunity, vol. 21, no. 5, pp. 599–616, 2007.
- E. D. Milligan, V. Zapata, M. Chacur et al., “Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats,” European Journal of Neuroscience, vol. 20, no. 9, pp. 2294–2302, 2004.
- I. N. Johnston, E. D. Milligan, J. Wieseler-Frank et al., “A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine,” The Journal of Neuroscience, vol. 24, no. 33, pp. 7353–7365, 2004.
- W. Zhu, E. E. Frost, F. Begum et al., “The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis,” Journal of Cellular and Molecular Medicine, vol. 16, no. 8, pp. 1856–1865, 2012.
- M. Melanson, P. Miao, D. Eisenstat et al., “Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia,” Multiple Sclerosis, vol. 15, no. 10, pp. 1135–1145, 2009.
- F. Begum, W. Zhu, M. P. Namaka, and E. E. Frost, “A novel decalcification method for adult rodent bone for histological analysis of peripheral-central nervous system connections,” The Journal of Neuroscience Methods, vol. 187, no. 1, pp. 59–66, 2010.
- K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88, 1988.
- K. A. Moller, B. Johansson, and O. Berge, “Assessing mechanical allodynia in the rat paw with a new electronic algometer,” The Journal of Neuroscience Methods, vol. 84, no. 1-2, pp. 41–47, 1998.
- O. Sporkel, T. Uschkureit, H. Bussow, and W. Stoffel, “Oligodendrocytes expressing exclusively the DM20 isoform of the proteolipid protein gene: myelination and development,” Glia, vol. 37, no. 1, pp. 19–30, 2002.
- E. Wang, Z. Huang, G. M. Hobson et al., “PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer,” Journal of Cellular Biochemistry, vol. 97, no. 5, pp. 999–1016, 2006.
- M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976.
- E. Mix, H. Meyer-Rienecker, and U. K. Zettl, “Animal models of multiple sclerosis for the development and validation of novel therapies—potential and limitations,” Journal of Neurology, vol. 255, supplement 6, pp. 7–14, 2008.
- M. Namaka, D. Turcotte, C. Leong, A. Grossberndt, and D. Klassen, “Multiple sclerosis: etiology and treatment strategies,” Consultant Pharmacist, vol. 23, no. 11, pp. 886–896, 2008.
- S. A. Aicher, M. B. Silverman, C. W. Winkler, and B. F. Bebo Jr., “Hyperalgesia in an animal model of multiple sclerosis,” Pain, vol. 110, no. 3, pp. 560–570, 2004.
- P. Miao, K. Madec, Y. Gong et al., “Axotomy-induced up-regulation of tumor necrosis factor-alpha in the dorsal root ganglia,” Neurological Research, vol. 30, no. 6, pp. 623–631, 2008.
- C. Solaro, E. Trabucco, and M. M. Uccelli, “Pain and multiple sclerosis: pathophysiology and treatment,” Current Neurology and Neuroscience Reports, vol. 13, no. 1, p. 320, 2013.
- P. L. Foley, H. M. Vesterinen, B. J. Laird et al., “Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis,” Pain, vol. 154, no. 5, pp. 632–642, 2013.
- J. G. D'Haese, I. E. Demir, H. Friess, and G. O. Ceyhan, “Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential,” Expert Opinion on Therapeutic Targets, vol. 14, no. 2, pp. 207–219, 2010.
- A. Ludwig, C. Hundhausen, M. H. Lambert et al., “Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules,” Combinatorial Chemistry and High Throughput Screening, vol. 8, no. 2, pp. 161–171, 2005.
- A. A. Staniland, A. K. Clark, R. Wodarski et al., “Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice,” Journal of Neurochemistry, vol. 114, no. 4, pp. 1143–1157, 2010.
- A. K. Clark, P. K. Yip, and M. Malcangio, “The liberation of fractalkine in the dorsal horn requires microglial cathepsin S,” The Journal of Neuroscience, vol. 29, no. 21, pp. 6945–6954, 2009.
- C. Coddou, S. S. Stojilkovic, and J. P. Huidobro-Toro, “Allosteric modulation of ATP-gated P2X receptor channels,” Reviews in the Neurosciences, vol. 22, no. 3, pp. 335–354, 2011.
- A. K. Clark, A. A. Staniland, F. Marchand, T. K. Y. Kaan, S. B. McMahon, and M. Malcangio, “P2X7-dependent release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide,” The Journal of Neuroscience, vol. 30, no. 2, pp. 573–582, 2010.
- T. Matsumiya, K. Ota, T. Imaizumi, H. Yoshida, H. Kimura, and K. Satoh, “Characterization of synergistic induction of CX3CL1/fractalkine by TNF-α and IFN-γ in vascular endothelial cells: an essential role for TNF-α in post-transcriptional regulation of CX3CL1,” Journal of Immunology, vol. 184, no. 8, pp. 4205–4214, 2010.
- M. J. Sung, D. Kim, M. Davaatseren et al., “Genistein suppression of TNF-α-induced fractalkine expression in endothelial cells,” Cellular Physiology and Biochemistry, vol. 26, no. 3, pp. 431–440, 2010.
- D. Huang, F. Shi, S. Jung et al., “The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system,” The FASEB Journal, vol. 20, no. 7, pp. 896–905, 2006.
- J. H. Mills, L. M. Alabanza, D. A. Mahamed, and M. S. Bynoe, “Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis,” Journal of Neuroinflammation, vol. 9, p. 193, 2012.
- L. R. Watkins and S. F. Maier, “Glia: a novel drug discovery target for clinical pain,” Nature Reviews Drug Discovery, vol. 2, no. 12, pp. 973–985, 2003.
- S. Sweitzer, D. Martin, and J. A. DeLeo, “Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain,” Neuroscience, vol. 103, no. 2, pp. 529–539, 2001.
- S. M. Sweitzer, P. Schubert, and J. A. DeLeo, “Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 3, pp. 1210–1217, 2001.
- S. Kastenbauer, U. Koedel, M. Wick, B. C. Kieseier, H. Hartung, and H. Pfister, “CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system,” Journal of Neuroimmunology, vol. 137, no. 1-2, pp. 210–217, 2003.
- C. Gomes, R. Ferreira, J. George et al., “Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia,” Journal of Neuroinflammation, vol. 10, p. 16, 2013.